Experienced in Cyclic Neutropenia

Dr. Sumithira Vasu

Hematology
The Osuccc-James
460 W 10th Ave, 
Columbus, OH 
Clinical Trials:Currently Recruiting for 1 Trial
19 Years of Experience
Experienced in Cyclic Neutropenia
The Osuccc-James
460 W 10th Ave, 
Columbus, OH 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Sumithira Vasu is a Hematologist in Columbus, Ohio. Dr. Vasu has been practicing medicine for over 19 years and is rated as an Experienced provider by MediFind in the treatment of Cyclic Neutropenia. Her top areas of expertise are Acute Myeloid Leukemia (AML), Graft Versus Host Disease (GvHD), Leukemia, Bone Marrow Transplant, and Islet Cell Transplantation.

Her clinical research consists of co-authoring 125 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Licenses
Internal Medicine in OH
Hospital Affiliations
Ohio State University State Health System
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Buckeye Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
CareFirst
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medical Mutual
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 8 Less Insurance Carriers -

Locations

The Osuccc-James
460 W 10th Ave, Columbus, OH 43210
Other Locations
Select Specialty Hosp-Columbus
410 W 10th Ave, Columbus, OH 43210

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Pilot Study of Haploidentical or Matched Donor Virus-Specific T-cells (Cytomegalovirus (CMV) or Adenovirus (AdV)) to Treat CMV or AdV Reactivation or Disease in Patients After Solid Organ or Hematopoietic Stem Cell Transplantation (HCT)
Pilot Study of Haploidentical or Matched Donor Virus-Specific T-cells (Cytomegalovirus (CMV) or Adenovirus (AdV)) to Treat CMV or AdV Reactivation or Disease in Patients After Solid Organ or Hematopoietic Stem Cell Transplantation (HCT)
Enrollment Status: Recruiting
Publish Date: November 19, 2025
Intervention Type: Biological
Study Phase: Early Phase 1
A Phase I Clinical Trial Testing the Safety of IL-21-Expanded, Off-the-shelf, Third-party Natural Killer Cells (KDS-1001) for the Induction of Relapsed/Refractory Acute Myeloid Leukemia
A Phase I Clinical Trial Testing the Safety of IL-21-Expanded, Off-the-shelf, Third-party Natural Killer Cells (KDS-1001) for the Induction of Relapsed/Refractory Acute Myeloid Leukemia
Enrollment Status: Completed
Publish Date: January 09, 2026
Intervention Type: Biological, Drug
Study Drugs: Cytarabine, Cytarabine Hydrochloride, Decitabine, Fludarabine, Fludarabine Phosphate, Membrane-bound Interleukin-21-Expanded Haploidentical Natural Killer Cells
Study Phase: Phase 1
Phase II Study of Maintenance Ruxolitinib After Allogeneic Stem Cell Transplantation for Older Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) in Complete Remission
Phase II Study of Maintenance Ruxolitinib After Allogeneic Stem Cell Transplantation for Older Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) in Complete Remission
Enrollment Status: Active_not_recruiting
Publish Date: July 14, 2025
Intervention Type: Drug
Study Drug: Ruxolitinib
Study Phase: Phase 2
Phase I/II Clinical Trial of Daratumumab and Donor Lymphocyte Infusion in Patients With Relapsed Acute Myeloid Leukemia Post-Allogeneic Hematopoietic Stem Cell Transplant
Phase I/II Clinical Trial of Daratumumab and Donor Lymphocyte Infusion in Patients With Relapsed Acute Myeloid Leukemia Post-Allogeneic Hematopoietic Stem Cell Transplant
Enrollment Status: Terminated
Publish Date: May 21, 2025
Intervention Type: Procedure, Biological, Other
Study Drug: Daratumumab
Study Phase: Phase 1/Phase 2
Tagraxofusp in Patients With Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Tagraxofusp in Patients With Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Enrollment Status: Completed
Publish Date: August 01, 2024
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1 / 2 Study to Evaluate the Safety, Tolerability and Initial Anti-Tumor Activity of Adoptively Transferred T Lymphocytes Targeting WT1, PRAME and Cyclin A1 AML or MDS Patients With Relapsed Disease After Matched Allogeneic HCT
A Phase 1 / 2 Study to Evaluate the Safety, Tolerability and Initial Anti-Tumor Activity of Adoptively Transferred T Lymphocytes Targeting WT1, PRAME and Cyclin A1 AML or MDS Patients With Relapsed Disease After Matched Allogeneic HCT
Enrollment Status: Unknown
Publish Date: January 16, 2024
Intervention Type: Biological
Study Drug: NEXI-001 T Cell Infusion
Study Phase: Phase 1/Phase 2
A Blinded, Prospective Non-Interventional Observational Study for the Evaluation of a GVHD Negative Outcome Score (GNOS) in Matched Unrelated or Haploidentical Hematopoietic Stem Cell Transplant
A Blinded, Prospective Non-Interventional Observational Study for the Evaluation of a GVHD Negative Outcome Score (GNOS) in Matched Unrelated or Haploidentical Hematopoietic Stem Cell Transplant
Enrollment Status: Completed
Publish Date: February 04, 2021
A Multi-Center, Phase II Cross-sectional Study Investigating Quality of Life in Older vs. Younger Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes: a Companion Study to the CIBMTR 10-CMSMDS-1-Approved Expanded Access Study
A Multi-Center, Phase II Cross-sectional Study Investigating Quality of Life in Older vs. Younger Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes: a Companion Study to the CIBMTR 10-CMSMDS-1-Approved Expanded Access Study
Enrollment Status: Completed
Publish Date: December 02, 2020
Intervention Type: Behavioral
Phase I Study of Decitabine and Haplo-identical Natural Killer Cells in Acute Myeloid Leukemia (AML)
Phase I Study of Decitabine and Haplo-identical Natural Killer Cells in Acute Myeloid Leukemia (AML)
Enrollment Status: Completed
Publish Date: March 09, 2020
Intervention Type: Other, Drug, Biological
Study Phase: Phase 1
A Phase 1b Dose-escalation Study of SGN-CD33A in Combination With Standard-of-care for Patients With Newly Diagnosed Acute Myeloid Leukemia
A Phase 1b Dose-escalation Study of SGN-CD33A in Combination With Standard-of-care for Patients With Newly Diagnosed Acute Myeloid Leukemia
Enrollment Status: Completed
Publish Date: May 09, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 9 Less Clinical Trials

125 Total Publications

Durable post-transplant survival after first-line tagraxofusp for blastic plasmacytoid dendritic cell neoplasm.
Durable post-transplant survival after first-line tagraxofusp for blastic plasmacytoid dendritic cell neoplasm.
Journal: Leukemia & lymphoma
Published: December 17, 2025
Similar Doctors
Advanced in Cyclic Neutropenia
Dr. Regina Crawford
Hematology
Advanced in Cyclic Neutropenia
Dr. Regina Crawford
Hematology

Office

181 Taylor Ave Fl 13, 
Columbus, OH 
 (10.9 miles away)
614-293-9441
Languages Spoken:
English
See accepted insurances

Regina Crawford is a Hematologist in Columbus, Ohio. Dr. Crawford is rated as a Distinguished provider by MediFind in the treatment of Cyclic Neutropenia. Her top areas of expertise are Sickle Cell Disease, Hemoglobinopathy, Hemoglobin SC Disease, Hemoglobin C Disease, and Bone Marrow Aspiration.

Advanced in Cyclic Neutropenia
Dr. Robert Rupert
Hematology
Advanced in Cyclic Neutropenia
Dr. Robert Rupert
Hematology

Memorial Hospital Of Union County

500 London Ave, 
Marysville, OH 
 (17.0 miles away)
937-578-2275
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Robert Rupert is a Hematologist in Marysville, Ohio. Dr. Rupert is rated as a Distinguished provider by MediFind in the treatment of Cyclic Neutropenia. His top areas of expertise are Adenoid Cystic Carcinoma, Laryngeal Cancer, Childhood Iron Deficiency Anemia, and Colorectal Cancer.

Experienced in Cyclic Neutropenia
Dr. Sanjay Yadav
Hematology
Experienced in Cyclic Neutropenia
Dr. Sanjay Yadav
Hematology

Hematology Oncology Consultantsinc

5141 W Broad St Ste 130, 
Columbus, OH 
 (9.2 miles away)
614-566-8612
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Sanjay Yadav is a Hematologist in Columbus, Ohio. Dr. Yadav is rated as a Distinguished provider by MediFind in the treatment of Cyclic Neutropenia. His top areas of expertise are Childhood Iron Deficiency Anemia, Iron Deficiency Anemia, Paget Disease of the Breast, and Schnitzler Syndrome.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Vasu's expertise for a condition
ConditionClose
View All 9 Distinguished Conditions
View All 10 Advanced Conditions
View All 38 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile